Guardant Health, Inc. (GH)
After hours:
| Previous close | 42.26 |
| Open | 42.08 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1200 |
| Day's range | 41.47 - 43.53 |
| 52-week range | 27.65 - 133.82 |
| Volume | |
| Avg. volume | 1,491,864 |
| Market cap | 4.285B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.13 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 117.73 |
- Business Wire
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
PALO ALTO, Calif., June 13, 2022--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.
- Motley Fool
Why Shares of Guardant Health Dropped 33.6% in May
It's a bit early for investors to jump the ship regarding Guardant because the biotech stock still has plenty of good long-term prospects. The test will compete with the Galleri blood-based cancer screening by the Grail unit of Illumina and a the Cologuard fecal screening by Exact Sciences. Investors are also watching the outcome of a lawsuit, filed in March by Illumina, that claims that Guardant and two of its founders -- former employees of Illumina -- used Illumina's propriety information to help them launch Guardant.
- Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
REDWOOD CITY, Calif., May 26, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
